Skip to main content
SpringerLink
Log in

Genetic Implications of Ocular Melanoma

  • Chapter
  • First Online:
Book cover Ocular Oncology

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

  • 353 Accesses

Abstract

Uveal melanoma treatment has good local control but still half the patients develop metastatic disease and the systemic prognosis when metastasis develops is still poor. Hence there is a need to identify high-risk features for early detection and targeted therapeutic treatment. The cytogenetics of uveal melanoma has come a long way with still unanswered questions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.

    Article  PubMed  Google Scholar 

  2. Virgili G, et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol. 2008;126(10):1413–8.

    Article  PubMed  Google Scholar 

  3. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–93.

    Article  Google Scholar 

  4. Vasalaki M, et al. Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. Br Med Bull. 2017;121(1):107–19.

    Article  PubMed  CAS  Google Scholar 

  5. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670–6.

    Article  Google Scholar 

  6. Diener-West M, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005;123(12):1639–43.

    Article  PubMed  Google Scholar 

  7. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13(2):123–32.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Jamal RT, Makitie T, Kivela T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 2003;44(6):2381–9.

    Article  PubMed  Google Scholar 

  9. White VA, et al. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83(2):354–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sisley K, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22–8.

    Article  CAS  PubMed  Google Scholar 

  11. Scholes AG, et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44(3):1008–11.

    Article  PubMed  Google Scholar 

  12. Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63(2):93–102.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Augsburger JJ, Correa ZM, Trichopoulos N. Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy. Arq Bras Oftalmol. 2013;76(2):72–9.

    Article  PubMed  Google Scholar 

  14. Chang MY, McCannel TA. Comparison of uveal melanoma cytopathologic sample retrieval in trans-scleral versus vitrectomy-assisted transvitreal fine needle aspiration biopsy. Br J Ophthalmol. 2014;98(12):1654–8.

    Article  PubMed  Google Scholar 

  15. Schopper VJ, Correa ZM. Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous. 2016;2:4.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst. 1990;82(22):1765–9.

    Article  CAS  PubMed  Google Scholar 

  17. Patel KA, et al. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol. 2001;85(12):1440–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shields CL, et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle lecture. Ophthalmology. 2017;124(10):1523–31.

    Article  PubMed  Google Scholar 

  19. Tschentscher F, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61(8):3439–42.

    CAS  PubMed  Google Scholar 

  20. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet. 1998;102(1):40–5.

    Article  CAS  PubMed  Google Scholar 

  21. Aalto Y, et al. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(2):313–7.

    CAS  PubMed  Google Scholar 

  22. Damato B, et al. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50(7):3048–55.

    Article  PubMed  Google Scholar 

  23. Kilic E, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46(7):2253–7.

    Article  PubMed  Google Scholar 

  24. Tschentscher F, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578–84.

    CAS  PubMed  Google Scholar 

  25. Onken MD, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Onken MD, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66(9):4602–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chang SH, et al. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008;18(3):191–200.

    Article  CAS  PubMed  Google Scholar 

  28. Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243–52.

    Article  CAS  Google Scholar 

  29. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

    Article  PubMed  Google Scholar 

  30. Walter SD, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134(7):734–40.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Damato B, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–31.

    Article  PubMed  Google Scholar 

  32. Augsburger JJ, Correa ZM, Augsburger BD. Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy. Am J Ophthalmol. 2015;159(2):248–56.

    Article  PubMed  Google Scholar 

  33. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Saldanha G, et al. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 2004;111(5):705–10.

    Article  CAS  PubMed  Google Scholar 

  35. Zuidervaart W, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92(11):2032–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fecher LA, et al. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606–20.

    Article  CAS  PubMed  Google Scholar 

  37. van den Bosch T, et al. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract. 2010;2010:360136.

    PubMed  PubMed Central  Google Scholar 

  38. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  39. Pollock PM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.

    Article  CAS  PubMed  Google Scholar 

  40. Onken MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230–4.

    Article  PubMed  Google Scholar 

  41. Van Raamsdonk CD, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.

    Article  PubMed  CAS  Google Scholar 

  42. Van Raamsdonk CD, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.

    Article  CAS  PubMed  Google Scholar 

  44. Bauer J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009;101(5):813–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Harbour JW, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Jensen DE, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097–112.

    Article  CAS  PubMed  Google Scholar 

  47. Dey A, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337(6101):1541–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Gupta MP, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133(8):881–7.

    Article  PubMed  Google Scholar 

  49. Rai K, et al. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94.

    Article  CAS  PubMed  Google Scholar 

  50. Rednam KR, et al. Uveal melanoma in association with multiple malignancies. A case report and review. Retina. 1981;1(2):100–6.

    Article  CAS  PubMed  Google Scholar 

  51. Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30(2):102–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Helgadottir H, Hoiom V. The genetics of uveal melanoma: current insights. Appl Clin Genet. 2016;9:147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yavuzyigitoglu S, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118–28.

    Article  PubMed  Google Scholar 

  56. Martin M, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45(8):933–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Decatur CL, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119–27.

    Article  PubMed  Google Scholar 

  59. Patel M, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17(8):2087–100.

    Article  CAS  PubMed  Google Scholar 

  60. Sagoo MS, et al. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene. 2014;33(39):4722–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Amirouchene-Angelozzi N, et al. Upcoming translational challenges for uveal melanoma. Br J Cancer. 2015;113(12):1746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Ambrosini G, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18(13):3552–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov. 2013;3(7):OF8.

    Google Scholar 

  64. Carvajal RD. et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. American Society of Clinical Oncology; 2012.

    Google Scholar 

  65. Carvajal RD, et al. Effect of selumetinib vs. chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311(23):2397–405.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Oncology Service, Moorfields Eye Hospital, London, UK

    Mona Mohammad & Mandeep S. Sagoo

  2. NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK

    Mandeep S. Sagoo

Authors
  1. Mona Mohammad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mandeep S. Sagoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mandeep S. Sagoo .

Editor information

Editors and Affiliations

  1. University of Louisville, Louisville, KY, USA

    Aparna Ramasubramanian

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mohammad, M., Sagoo, M.S. (2019). Genetic Implications of Ocular Melanoma. In: Ramasubramanian, A. (eds) Ocular Oncology . Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7538-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7538-5_3

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7537-8

  • Online ISBN: 978-981-13-7538-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation